Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: RAIN) | Delayed: 0.53 -0.02 (3.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.55 | 52 Week High | $ | |||
| Open | $0.53 | 52 Week Low | $ | |||
| Day High | $0.55 | P/E | N/A | |||
| Day Low | $0.52 | EPS | $ | |||
| Volume | 7,528 | |||||
